Novo Nordisk (ADR) (NVO)
Develops GLP-1 and insulin medicines for diabetes, obesity and rare diseases.
$39.32
vs last close−0.48 (−1.22%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 7.34% | 327.95M ADS | |
|---|---|---|---|
| 1,454 holders · as of Jun 30, 2026 | |||
| Other | 92.66% | 4.14B ADS | |
| remainder | |||
4.47B ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
1,454 holders · 327.95M shares · 221 new positions · 688 increased · 462 reduced · 137 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Dodge & Cox | 20.40M | 0.46% | +1.06M | Aug 13, 2026 |
| Loomis Sayles & Co L P | 18.59M | 0.42% | +1.58M | Aug 14, 2026 |
| Franklin Resources Inc | 13.04M | 0.29% | −3.04M | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 11.70M | 0.26% | +644.0K | Aug 14, 2026 |
| Morgan Stanley | 11.66M | 0.26% | +790.7K | Aug 13, 2026 |
| Bank of America Corp /DE/ | 11.18M | 0.25% | +407.0K | Aug 14, 2026 |
| Capital International Investors | 9.72M | 0.22% | −2.07M | Aug 12, 2026 |
| Folketrygdfondet | 9.52M | 0.21% | +441.6K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.20% | 177.80M | 13G | Apr 23, 2025 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Scott Mr Franklin · FL18 | Purchase | $1,001 – $15,000 | Aug 26, 2026 | Sep 18, 2026 | |
| Rep. Scott Franklin · FL18 | Purchase | $1,001 – $15,000 | Aug 26, 2026 | Sep 18, 2026 |